within Pharmacolibrary.Drugs.ATC.N;

model N06BA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.67,
    Cl             = 3.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,
    adminCount     = 1,
    Vd             = 0.0053,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Metamfetamine (also known as methamphetamine) is a potent central nervous system stimulant, formerly used clinically for attention deficit hyperactivity disorder (ADHD), obesity, and narcolepsy. Due to its high potential for abuse and neurotoxicity, its clinical use is now highly restricted or prohibited in most countries. It is not widely approved for therapeutic use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults following oral administration, derived from available clinical and pharmacological literature on methamphetamine, since no standard clinical PK model referenced with DOIs is available.</p><h4>References</h4><ol><li><p>Gerlach, M, et al., &amp; Riederer, P (1996). Pharmacology of selegiline. <i>Neurology</i> 47(6 Suppl 3) S137–S145. DOI:<a href=&quot;https://doi.org/10.1212/wnl.47.6_suppl_3.137s&quot;>10.1212/wnl.47.6_suppl_3.137s</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8959982/&quot;>https://pubmed.ncbi.nlm.nih.gov/8959982</a></p></li><li><p>Poyatos, L, et al., &amp; Farré, M (2022). Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans. <i>International journal of molecular sciences</i> 23(23) –. DOI:<a href=&quot;https://doi.org/10.3390/ijms232314636&quot;>10.3390/ijms232314636</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36498963/&quot;>https://pubmed.ncbi.nlm.nih.gov/36498963</a></p></li><li><p>Schepers, RJ, et al., &amp; Huestis, MA (2003). Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. <i>Clinical chemistry</i> 49(1) 121–132. DOI:<a href=&quot;https://doi.org/10.1373/49.1.121&quot;>10.1373/49.1.121</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12507968/&quot;>https://pubmed.ncbi.nlm.nih.gov/12507968</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06BA03;
